News

06 / 02 / 2023

At ASCO ’23, AI Precision Oncology Company Perthera Unveils Premium Experience for Clinicians with New Options for Ordering and Access to Enhanced Perthera Analytics

Chicago, IL // In advance of a new Current Procedural Terminology (CPT) Category III code that will go into effect on July 1st, Perthera, the leader in AI precision oncology solutions, introduced its latest generation of clinical support tools, including Perthera Lab Direct and Perthera RWE Navigator. As part of this new, enhanced clinician experience, Perthera Lab Direct will make it easier to order reports, delivering results faster and the Perthera RWE Navigator will provide clinicians direct access to Perthera’s powerful analytics. The Category III CPT code provides a critical pathway to reimbursement and wider adoption of AI-assisted Oncology decision support. The new multi-ordering platform and expanded analytics bench are intended to help support increased clinician demand.

02 / 08 / 2023

Perthera.ai Announces a Category III CPT Code from the AMA for its Patented Precision Oncology Decision Support Platform

McLean, VA // Perthera.ai, the industry leader in Oncology Decision Support, announces the release by the American Medical Association of a new Current Procedural Terminology (CPT) Category III code, 0794T, clearly recognizing the increasing importance of AI-assisted decision support in delivering precision oncology care. Perthera.ai is a pioneer in personalized AI-assisted Oncology decision support with its patented ranked therapy options presented in the Perthera Report created by our Precision Oncology Platform.

10 / 10 / 2022

Massive Bio and Perthera.ai Partner to Empower Cancer Patients with Personalized Therapies and Accurate Trial Recommendations

New York, NY & McLean, VA // Massive Bio has announced a partnership with Perthera.ai. Perthera.ai’s ranked therapy recommendations will complement Massive Bio’s screening and analysis to aid more cancer patients in finding an appropriate clinical trial.

Partnerships

Applied Clinical Trials Business Wire

06 / 08 / 2022

ACCRU, a Cancer Research Network Operating Within the Mayo Clinic, has Officially Partnered with Perthera

A leading precision oncology company, to bring innovative clinical trials to cancer patients throughout the country in the Target Panc Program. Perthera, with its Oncology Operating System™, will serve as the centralized “Molecular CRO” under the umbrella protocol.

Partnerships

ACCRU PDF

06 / 06 / 2022

ASCO ’22: Perthera Announces the Immediate Availability of the Perthera AI Analytics Platform to Cancer Centers for Improved Analytics, Clinical Trial Optimization and Patient Care Management

Chicago, IL // For the first time, Perthera AI’s proven data mining, analytics, optimization and care management platform is now available as an analytics solution for cancer centers to utilize with their own patient data, at no cost. A research study by Cedars Sinai, PanCAN and Perthera’s GIPOCS program was one of the first to utilize data from Perthera’s Analytics solution and was presented at ASCO ‘22.

AIClinical TrialsDecision SupportPrecision OncologyRWE

PDF

05 / 25 / 2022

Comprehensive Analysis of KRAS Variants in Patients (Pts) with Pancreatic Cancer

Molecular profiling in pancreatic adenocarcinoma (PDAC) has gained traction and we recently demonstrated that targeting actionable alterations can improve patient (pt) outcomes using the Perthera Platform’s real-world evidence database.

Clinical ResearchPrecision OncologyRWE

Journal of Clinical Oncology PDF

11 / 16 / 2020

Perthera and Theralink Technologies Announce Partnership to Allow for Unique Access to Phosphoproteomic Profiling and Drug Target Activation Testing

Denver, CO // The new partnership will give oncologists who use Perthera access to the world’s only phosphoprotein panel LDT that directly measures the activation state of targets of over 100 precision therapeutics at once. Perthera will serve as Theralink’s CRO to help bring in and enroll oncology practices in Theralink’s TRACE program, as well as provide treatment matching services to Theralink’s oncology partners.

Clinical ResearchClinical TrialsMolecular ProfilingPartnerships

PR Newswire PDF

07 / 13 / 2020

Perthera and Fight Colorectal Cancer Announce Partnership to Deliver Precision Oncology to Patients with Cancer

Holliston, MA // The collaborative effort will deliver molecular profiling, personalized treatment recommendations, and clinical trial matching to patients with colorectal cancer.

PartnershipsPrecision Oncology

Fight Colorectal Cancer PDF

03 / 12 / 2020

GenomeWeb: Perthera’s Molecular Tumor Board Improves Patient Outcomes and Overcomes Barriers

New York, NY // GenomeWeb interviews Perthera CEO Gary Gregory and CMO Mike Pishvaian about the Perthera Platform’s proven results, the capabilities of Perthera’s molecular tumor board, and how precision medicine is changing the landscape of cancer care today.

Clinical ResearchDecision SupportMolecular ProfilingRWEvMTB

GenomeWeb PDF

03 / 02 / 2020

Perthera and PanCAN Publish Pivotal Paper in Lancet Oncology Highlighting the Importance of Selecting Treatments Based on Tumor Mutations

This is the first study to demonstrate an overall survival benefit from precision medicine in pancreatic cancer patients. Patients who receive precision medicine live an average of one year longer than those who do not.